Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients

被引：208
作者：
Zervas, Kostas
Verrou, Evgenia
Teleioudis, Zisis
Vahtsevanos, Konstantinos
Banti, Anastasia
Mihou, Dimitra
Krikelis, Dimitris
Terpos, Evangelos
机构：
[1] Gen Airforce Hosp, Dept Haematol & Med Res, GR-11525 Athens, Greece
[2] Theagen Canc Ctr, Dept Haematol Oncol, Thessaloniki, Greece
[3] Theagen Canc Ctr, Dept Oral & Maxillofacial Surg, Thessaloniki, Greece
[4] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Haematol, London, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2006年 / 134卷 / 06期
关键词：
multiple myeloma; osteonecrosis of the jaw; bisphosphonates; pamidronate; zoledronic acid;
D O I：
10.1111/j.1365-2141.2006.06230.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The incidence, characteristics and risk factors for the development of osteonecrosis of the jaw (ONJ) were evaluated among 303 myeloma patients. Only patients who received bisphosphonates developed ONJ (28/ 254; 11%). Zoledronic acid produced 9.5-fold greater risk for developing ONJ than pamidronate alone (P = 0.042) and 4.5-fold greater risk than subsequent use of pamidronate + zoledronic acid (P = 0.018). Use of thalidomide and number of bisphosphonate infusions also increased the risk for ONJ by 2.4-fold (P = 0.043), and 4.9-fold respectively (P = 0.012). ONJ developed earlier among patients receiving zoledronic acid. Our data indicates that administration of zoledronic acid for more than 2 years or in combination with thalidomide requires caution in myeloma.
引用
收藏
页码：620 / 623
页数：4
相关论文
共 12 条
[1]   Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors [J].
Badros, A ;
Weikel, D ;
Salama, A ;
Goloubeva, O ;
Schneider, A ;
Rapoport, A ;
Fenton, R ;
Gahres, N ;
Sausville, E ;
Ord, R ;
Meiller, T .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :945-952
[2]   Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].
Bamias, A ;
Kastritis, E ;
Bamia, C ;
Moulopoulos, LA ;
Melakopoulos, L ;
Bozas, G ;
Koutsoukou, V ;
Gika, D ;
Anagnostopoulos, A ;
Papadimitriou, C ;
Terpos, E ;
Dimopoulos, MA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587
[3]   American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma [J].
Berenson, JR ;
Hillner, BE ;
Kyle, RA ;
Anderson, K ;
Lipton, A ;
Yee, GC ;
Biermann, JS .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3719-3736
[4]   Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events [J].
Berenson, JR ;
Lichtenstein, A ;
Porter, L ;
Dimopoulos, MA ;
Bordoni, R ;
George, S ;
Lipton, A ;
Keller, A ;
Ballester, O ;
Kovacs, M ;
Blacklock, H ;
Bell, R ;
Simeone, JF ;
Reitsma, DJ ;
Heffernan, M ;
Seaman, J ;
Knight, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) :593-602
[5]  
Durie B. G. M., 2005, HAEMATOLOGICA, V90
[6]  
Durie BGM, 2005, NEW ENGL J MED, V353, P99
[7]   AGE-CHANGES IN THE HUMAN INFERIOR ALVEOLAR ARTERY - A HISTOLOGICAL STUDY [J].
MCGREGOR, AD ;
MACDONALD, DG .
BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 1989, 27 (05) :371-374
[8]   Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer [J].
Ruggiero, Salvatore ;
Gralow, Julie ;
Marx, Robert E. ;
Hoff, Ana O. ;
Schubert, Mark M. ;
Huryn, Joseph M. ;
Toth, Bela ;
Damato, Kathryn ;
Valero, Vicente .
JOURNAL OF ONCOLOGY PRACTICE, 2006, 2 (01) :7-14
[9]  
Santini D, 2003, CLIN CANCER RES, V9, P2893
[10]   Medullary and odontogenic disease in the painful jaw: Clinicopathologic review of 500 consecutive lesions [J].
Shankland, WE .
CRANIO-THE JOURNAL OF CRANIOMANDIBULAR & SLEEP PRACTICE, 2002, 20 (04) :295-303
12